
Vaccine, Journal Year: 2025, Volume and Issue: 55, P. 127062 - 127062
Published: March 31, 2025
Respiratory syncytial virus (RSV) is a major cause of respiratory infections and hospitalizations in Canadian infants. Recently, Health Canada approved two novel immunizing products: vaccine given during pregnancy monoclonal antibody for This study assessed knowledge, attitudes, intentions regarding RSV its prevention among pregnant individuals. A mixed-methods was conducted Quebec from October to December 2023. Pregnant individuals were recruited through targeted Facebook advertisements. Data collected phases: Phase 1 involved an online survey assess knowledge RSV, attitudes toward immunization, both immunization products, followed by qualitative interviews 2 explore factors impacting decision-making preferences prevention. Survey data analyzed using descriptive statistics; interview thematic analysis. Among participants (n = 803), 68.4 % reported some RSV. Intention products high, with 88.1 willing receive the 92 %, administer antibodies their majority (69 %) preferred vaccination over antibodies. The desire protect infant severe complications key motivating factor acceptance new products. Other determinants included safety, efficacy, recommendations healthcare providers. Qualitative 25) highlighted safety concerns expectant parents about these importance clear evidence-based providers also emphasized. demonstrated high level interest infants, whether or Recommendations availability information on efficacy will be move intention action.
Language: Английский